BTAI

1.805

4.50% -0.085

Handel nachbörslich: 1.80 -0.005 -0.28%

Bioxcel Therapeutics Inc (BTAI)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BTAI? Forum Prognose

Schlusskurs vom Vortag:

$1.89

Offen:

$1.92

24-Stunden-Volumen:

384.21K

Relative Volume:

1.30

Marktkapitalisierung:

$10.93M

Einnahmen:

$1.38M

Nettoeinkommen (Verlust:

$-179.05M

KGV:

-0.294

EPS:

-6.14

Netto-Cashflow:

$-155.03M

1W Leistung:

-5.00%

1M Leistung:

+12.81%

6M Leistung:

+396.56%

1J Leistung:

+50.42%

1-Tages-Spanne:

$1.7398

$1.92

1-Wochen-Bereich:

$1.7398

$2.0093

52-Wochen-Spanne:

$0.16

$6.83

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Firmenname

Bioxcel Therapeutics Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (653)

Telefon

203-643-8060

Adresse

555 LONG WHARF DRIVE, NEW HAVEN, CT

Mitarbeiter

Twitter

@bioxcel_tx

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

BTAI's Discussions on Twitter

Vergleichen Sie BTAI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BTAI Bioxcel Therapeutics Inc	1.805	11.51M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	470.13	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	560.93	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.28	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	571.23	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	295.59	29.19B	3.81B	-644.79M	-669.77M	-6.24

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-21	Herabstufung	UBS	Buy → Neutral
2023-08-15	Herabstufung	Mizuho	Buy → Neutral
2023-07-17	Herabstufung	Guggenheim	Buy → Neutral
2023-03-10	Herabstufung	Jefferies	Buy → Hold
2022-12-01	Hochstufung	Goldman	Sell → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-06	Bestätigt	BofA Securities	Buy
2021-11-15	Herabstufung	Goldman	Neutral → Sell
2021-04-09	Eingeleitet	Berenberg	Buy
2021-02-01	Eingeleitet	UBS	Buy
2020-10-30	Eingeleitet	Goldman	Buy
2020-09-02	Eingeleitet	Jefferies	Buy
2020-08-17	Bestätigt	H.C. Wainwright	Buy
2020-07-08	Bestätigt	H.C. Wainwright	Buy
2020-06-04	Eingeleitet	Guggenheim	Buy
2020-04-01	Eingeleitet	BofA/Merrill	Buy
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-12	Eingeleitet	SunTrust	Buy

Alle ansehen

Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten

Jul 22, 2025

BioXcel Therapeutics Inc. Stock Analysis and ForecastLightning-fast growth - jammulinksnews.com

Jul 22, 2025

BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada

Jul 22, 2025

What analysts say about BioXcel Therapeutics Inc. stockRapid wealth creation - jammulinksnews.com

Jul 22, 2025

BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire

Jul 22, 2025

Jul 21, 2025

What drives BioXcel Therapeutics Inc. stock priceSky-high return potential - Autocar Professional

Jul 21, 2025

Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest

Jul 21, 2025

BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com Australia

Jul 21, 2025

BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan

Jul 21, 2025

First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan

Jul 21, 2025

Jul 20, 2025

Is BioXcel Therapeutics Inc. a good long term investmentRobust investment performance - printweek.in

Jul 20, 2025

Jul 18, 2025

How high can BioXcel Therapeutics Inc. stock price go in 2025Capital Growth Picks - beatles.ru

Jul 18, 2025

Jul 16, 2025

why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser

Jul 16, 2025

What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser

Jul 16, 2025

BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest

Jul 16, 2025

Jul 15, 2025

BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus

Jul 15, 2025

BioXcel Therapeutics (BTAI) Gains Patent Approval, Price Target Affirmed | BTAI Stock News - GuruFocus

Jul 15, 2025

BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent By Investing.com - Investing.com South Africa

Jul 15, 2025

BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent - Investing.com Nigeria

Jul 15, 2025

BioXcel Granted Patent for Dexmedetomidine Use - TipRanks

Jul 15, 2025

Why BioXcel Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser

Jul 15, 2025

BioXcel wins USPTO nod; 14th Igalmi patent secures exclusivity to 2043 | BTAI SEC FilingForm 8-K - Stock Titan

Jul 15, 2025

How BioXcel Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser

Jul 15, 2025

Jul 11, 2025